April 30, 2014 / 2:10 PM / 3 years ago

Incorrect biopsy results cloud Nymox Pharma prostate cancer study

April 30 (Reuters) - Nymox Pharmaceutical Corp said its experimental prostate cancer drug reduced the progression of cancer in patients, but it could not determine if the study succeeded in meeting pre-determined goals due to a high rate of incorrect biopsies.

In the mid-stage study, patients receiving a single injection of the drug, NX-1207, had less cancer progression in the treated area than in untreated patients.

The main goal of the trial was to show a significantly higher number of patients with undetectable prostate cancer after 45 days of treatment, compared to untreated patients.

However, the company was unable to assess the drug's benefit because of a high percentage of false negative biopsies - a result suggesting there is no cancer present when it actually is - in the untreated patients' group.

Nymox's shares were down 3 percent at $4.98 in morning trading on the Nasdaq. (Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below